Oncology company BeiGene Ltd (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235) announced on Monday that it has received positive recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for extending the use of TEVIMBRA (tislelizumab) as a first-line treatment for advanced gastric, gastroesophageal junction (G/GEJ) cancer and esophageal squamous cell carcinoma (ESCC).
The decision for G/GEJ adenocarcinoma is based on the RATIONALE-305 trial, which showed TEVIMBRA, in combination with chemotherapy, improved overall survival by 20%, reducing the risk of death compared to placebo.
Similarly, for ESCC, the RATIONALE-306 trial demonstrated a 34% reduction in the risk of death, with TEVIMBRA offering significant survival benefits in combination with chemotherapy.
TEVIMBRA is already approved in the EU for ESCC following platinum-based chemotherapy and various non-small cell lung cancer (NSCLC) treatments. These new approvals further strengthen its presence in the oncology market.
Sanofi and Orano partner to advance radioligand therapies
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies